Search Results - "MOSENIFAR, Z"

The minimal important difference of exercise tests in severe COPD by PUHAN, M. A, CHANDRA, D, MOSENIFAR, Z, RIES, A, MAKE, B, HANSEL, N. N, WISE, R. A, SCIURBA, F

“…Our aim was to determine the minimal important difference (MID) for 6-min walk distance (6MWD) and maximal cycle exercise capacity (MCEC) in patients with…”
Get full text

Prevalence and clinical correlates of bronchoreversibility in severe emphysema by Han, M K, Wise, R, Mumford, J, Sciurba, F, Criner, G J, Curtis, J L, Murray, S, Sternberg, A, Weinman, G, Kazerooni, E, Fishman, A P, Make, B, Hoffman, E A, Mosenifar, Z, Martinez, F J

“…Chronic obstructive pulmonary disease (COPD) exhibits airflow obstruction that is not fully reversible. The importance of bronchoreversibility remains…”
Get full text

Pulmonary function in patients with Amyotrophic Lateral Sclerosis at disease onset by Chandrasoma, B., Balfe, D., Naik, T., Elsayegh, A., Lewis, M., Mosenifar, Z.

“…Background. Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder affecting both the upper and lower motor neurons. Deteriorating…”
Get full text

Pulmonary function in patients with amyotrophic lateral sclerosis at disease onset by Chandrasoma, B, Balfe, D, Naik, T, Elsayegh, A, Lewis, M, Mosenifar, Z

“…Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting both the upper and lower motor neurons. Deteriorating pulmonary…”
Get full text

Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced Emphysema by Slebos, Dirk-Jan, Sciurba, Frank C., Deslée, Gaëtan, Delage, Antoine, Mehta, Atul C., Shah, Pallav L., Herth, F.J.F., Gompelmann, D., Schuhmann, M., Eberhardt, R., Rump, B., Slebos, D.J., Ten Hacken, N., Klooster, K., Hartman, J.E., Augustijn, S., McNulty, W., Garner, J., Dury, S., Gras, D., Marquette, C.H., Sanfiorenzo, C., Clary, C., Leheron, C., Arfi, T., Leroy, S., Argula, R., Huggins, J.T., Pastis, N., Woodford, D., Walker, D., Criner, G., Marchetti, N., Garfield, J.L., Maxfield, R., Gillespie, C.T., Rogowski, A.S., Angel, L.F., Dib, O., Chandra, D., Crespo, M., Tedrow, J. Rahul, Beckner, M., Majid, A., Cardenas-Garcia, J., Beach, D., Agnew, A., Nathanson, A., Hartwig, M., Smathers, E., Tillis, W., Verma, K., Chittivelu, S., Doloszycki, P., Michel, J., Kopas, L., Krimsky, W., King, S., Mehta, A., Machuzak, M., Meli, Y.M., Baran, J., Rice, R., Faile, D., Kahlstrom, R., Haroon, A., White, F., Moore, B., Soukiasian, H., Merry, H., Mosenifar, Z., Balfe, D., Kanne, J., Sonetti, D., Maloney, J., Hackbarth, M., Gilles, M., Maser, A., Puchalski, J.T., Johnson, K., Dabre, Z., Kovitz, K., Joo, M., DeLisa, J., Krishna, G., Marfatia, A., Utz, J., Kern, R., Edell, E.S., Meldrum, C., Jantz, M., Eagan, C., Delage, A., LeBlanc, P., Lampron, N., Laberge, F., Milot, J., Breton, M.J., Dransfield, M., Seabron-Harris, E.N.

“…The Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) trial reported improvements in quality of life, pulmonary function, and exercise…”
Get full text

Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease by Falk, Jeremy A, Minai, Omar A, Mosenifar, Zab

“…Systemic and local inflammation is central to the pathophysiology of chronic obstructive pulmonary disease (COPD). Increased levels of inflammation have been…”
Get full text

Endobronchial coils for emphysema: Dual mechanism of action on lobar residual volume reduction by Hartman, Jorine E., Herth, Felix J.F., Slebos, Dirk‐Jan, Herth, F.J.F., Eberhardt, R., Rump, B., Slebos, D.J., Klooster, K., Hartman, J.E., Augustijn, S., McNulty, W., Garner, J., Vallerand, H., Dury, S., Gras, D., Sanfiorenzo, C., Leheron, C., Korzeniewski, S., Wolter, P., Arfi, T., Macone, F., Leroy, S., Griffonet, J., Strange, C., Argula, R., Huggins, J.T., Pastis, N., Woodford, D., Walker, D., Marchetti, N., Garfield, J.L., Srivastava‐Malhotra, S., Tauch, V., Maxfield, R., Brenner, K., DeCamp, M. McAvoy, Rogowski, A.S., Angel, L.F., Dib, O., Chandra, D., Tedrow, J. Rahul, Beckner, M., Cardenas‐Garcia, J., Beach, D., Nathanson, A., Smathers, E., Taneja, D., Chittivelu, S., Aulakh, B., Michel, J., Crabb, J., Gregoire, F., King, S., Mehta, A., Almeida, F., Machuzak, M., Meli, Y.M., Baran, J., Rice, R., Faile, D., Jensen, K., Kahlstrom, R., Ionita, R., Moore, B., Merry, H., Ghandehari, S., Balfe, D., Ferguson, J.S., Sonetti, D., Maloney, J., Hackbarth, M., Maser, A., Rochester, C., Johnson, K., Dabre, Z., Kovitz, K., Joo, M., Krishna, G., Canfield, J., Utz, J., Kern, R., Gay, S., Han, M. King, Sagana, R.L., Nelson, K., Meldrum, C., Jantz, M., Eagan, C., Delage, A., Martel, S., LeBlanc, P., Maltais, F., Lampron, N., Laberge, F., Milot, J., Picard, J., Breton, M.J., Wells, J.M., Bhatt, S., Smith, P.

“…Residual lobar volume reduction in treated lobes measured by QCT was found to be the driving mechanism of action of endobronchial coils leading to positive…”
Get full text

The inspiratory capacity/totallungcapacityratio as a predictor of survival in an emphysematous phenotype of chronic obstructive pulmonarydisease by French A, Balfe D, Mirocha JM, Falk JA, Mosenifar Z

“…Aimee French, David Balfe, James M Mirocha, Jeremy A Falk, Zab Mosenifar Cedars-Sinai Medical Center, Division of Pulmonary and Critical Care Medicine, Los…”
Get full text

Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease by Moy, Marilyn L, Reilly, John J, Ries, Andrew L, Mosenifar, Zab, Kaplan, Robert M, Lew, Robert, Garshick, Eric

“…Persons with severe chronic obstructive pulmonary disease (COPD) and similar levels of forced expiratory volume in 1 second (FEV(1)), exercise capacity, and…”
Get full text

Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease by Bierer, Gregory, Balfe, David, Wilcox, William R., Mosenifar, Zab

“…Summary Background. Fabry disease is an X‐linked genetic disorder resulting in the accumulation of glycosphingolipids in various organs, leading to exercise…”
Get full text

Cardiopulmonary exercise testing in Fabry disease by Bierer, Gregory, Kamangar, Nader, Balfe, David, Wilcox, William R, Mosenifar, Zab

“…Fabry disease is a rare X-linked disorder that results from a deficiency in a lysosomal enzyme known as alpha-galactosidase A, with accumulation of…”
Get more information

Population issues in clinical trials by Mosenifar, Zab

“…Inclusion of underrepresented groups in clinical trials is important for several reasons. Age, sex, race, genetic factors, concomitant use of other…”
Get full text

Short-term Influences of Lung Volume Reduction Surgery on the Diaphragm in Emphysematous Hamsters by Lewis, Michael I, Fournier, Mario, Da, Xiaoyu, Li, Hongmei, Mosenifar, Zab, McKenna, Robert J., Jr, Cohen, Arthur H

“…With emphysema, diaphragm length adaptation results in shortened fibers. We hypothesize that passive diaphragm stretch occurring acutely after lung volume…”
Get full text